Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -119K | -169K | -121K |
| Operating Income | -51M | -65M | -16M | -28M | -27M |
| EBITDA | -51M | -65M | -16M | -27M | -26M |
| Net Income | -50M | -63M | -16M | -27M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.11
+9.33% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Aileron Therapeutics, Inc. (ALRN) is a Healthcare stock with a market cap of $45.72M. The stock last traded around $2.11. Baseline metrics include revenue growth of 0.0%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +44.2%, free cash flow +13.1% with operating margin 0.0% and ROIC -120.3%. Stock Foundry combines ALRN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALRN
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALRN Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ALRN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$25.8M
+4.6% YoY
Free Cash Flow
-$23.9M
+3.8% YoY
Revenue Growth
+0.0%
EPS Growth
+44.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -119K | -169K | -121K |
| Operating Income | -51M | -65M | -16M | -28M | -27M |
| EBITDA | -51M | -65M | -16M | -27M | -26M |
| Net Income | -50M | -63M | -16M | -27M | -26M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 13M | 17M | 5M | 4M |
| Total Assets | 24M | 62M | 106M | 22M | 48M |
| Total Liabilities | 7M | 8M | 99M | 3M | 5M |
| Shareholder Equity | 17M | 54M | 7M | 19M | 44M |
| Total Debt | 0 | 0 | 48K | 33K | 162K |
| Net Debt | -3M | -13M | -17M | -5M | -3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
24M
+4.5% YoY
Capital Expenditures
157K
Free Cash Flow
24M
+3.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.